When is a branded drug maker obligated to turn over product samples to competitors working to develop cheaper generic versions?
A test of that question—an antitrust battle between Actelion Pharmaceuticals Ltd. and three of its generic rivals—settled on Friday without offering a definitive answer. But given the timing of the settlement and the history of the case, the obstacles appear steep for branded drug makers looking to keep their samples under wraps.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
